Welcome to CapLaw

On 24 June 2024, UBS Group AG completed its offering of SGD 500 million 5.600 per cent. Tier 1 Capital Notes, which are redeemable at the option of UBS Group AG for the first time on 21 December 2029. The Notes are “high trigger” regulatory capital instruments that are eligible to fulfil UBS Group AG’s Swiss going concern requirements. Upon occurrence of a “Trigger Event” or a “Viability Event”, the Notes will be converted into ordinary shares of UBS Group AG in accordance with their terms.

On 17 June 2024, Viseca placed CHF 165 million 1.65% senior bonds due 2028. The bonds were issued by Viseca Payment Services AG. Zürcher Kantonalbank, Raiffeisen Schweiz Genossenschaft and UBS acted as Joint Lead Managers.

On 19 June 2024, Novartis AG placed CHF bonds in the aggregate principal amount of CHF 2.2 billion in five tranches, with maturity dates ranging from 2027 to 2049. UBS, BNP Paribas (Suisse) SA and Deutsche Bank Aktiengesellschaft acted as Joint Lead Managers and Zürcher Kantonalbank acted as Co-Manager in this transaction.

On 17 May 2024 and 14 June 2024, respectively, Barry Callebaut issued CHF and EUR Bonds. Specifically, Barry Callebaut placed CHF 730 million bonds in the Swiss market on 17 May 2024 and issued EUR bonds in the amount of EUR 700 million on 14 June 2024. The issuances were made to achieve greater financial flexibility against the back­drop of the volatile cocoa bean price market environment.

On 3 June 2024, Warteck Invest launched its CHF 94.7 million capital increase by way of a rights offering. In the rights offering Warteck Invest shareholders were allocated subscription rights in proportion to their shareholdings in Warteck Invest. Shares not taken up by Warteck Invest shareholders were subsequently sold to investors in a share placement. Warteck Invest has issued 61,875 registered shares with a par value of CHF 10.00 each leading to gross proceeds in an amount of approximately CHF 94.7 million. The proceeds raised from the capital increase will be used to support the execution of Warteck Invest’s growth…

On 30 May 2024, St.Galler Kantonalbank AG (SGKB) successfully issued CHF 200 million 2.4% Tier 2 bonds due 2034. Zürcher Kantonalbank acted as Sole Lead Manager and SGKB as Co-Manager.

On 22 May 2024, UBS Group AG completed its issuance of CHF 335 million in aggregate principal amount of Fixed Rate/Fixed Rate Senior Notes due May 2030. Previously, on 13 May 2024, UBS Group AG completed its issuance of USD 1.75 billion in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due September 2030 under its Senior Debt Programme. The Notes are bail-inable (TLAC) bonds that are eligible to count towards UBS Group AG’s Swiss gone concern requirement.

On 21 May 2024, UBS Switzerland AG successfully completed its issuance of Covered Bonds under the program in an aggregate principal amount of EUR 1.75 billion, consisting of EUR 1 billion Floating Rate Covered Bonds due April 2027 and EUR 750 million 3.146% Covered Bonds due June 2031. The Covered Bonds are governed by Swiss law and are listed on SIX Swiss Exchange. The Covered Bonds are indirectly backed by a portfolio of mortgages from UBS Switzerland AG’s domestic mortgage pool.

On 6 May 2024, NYSE-listed ADC Therapeutics SA, a commercial-stage biotechnology company based in Lausanne, Switzerland, announced that it had agreed to sell, by way of an underwritten offering, 13.4 million of its common shares as well as pre-funded warrants to purchase 8.1 million common shares to raise aggregate gross proceeds of approx. USD 105 million.